危重心衰患者血红蛋白糖化指数与全因死亡率的关系:MIMIC-IV数据库的回顾性研究

IF 2 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Yulong Wang, Shanshan Tang, Haokun Liu, Yongle Li
{"title":"危重心衰患者血红蛋白糖化指数与全因死亡率的关系:MIMIC-IV数据库的回顾性研究","authors":"Yulong Wang, Shanshan Tang, Haokun Liu, Yongle Li","doi":"10.1186/s12872-025-04711-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a major cause of mortality in critically ill patients and often requires intensive care. The hemoglobin glycation index (HGI), defined as the difference between predicted glycated hemoglobin (HbA1c) and measured HbA1c, may provide additional prognostic insights beyond traditional glycemic metrics.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 8,098 adult patients with HF from the MIMIC-IV database (2008-2022). All were first-time ICU admissions with available hematologic and metabolic data. Patients were stratified into three groups (T1 ≤ - 1.26, - 1.26 < T2 < 1.74, T3 ≥ 1.74) based on HGI. Baseline characteristics were recorded within 24 h of ICU admission, including demographic data, disease severity scores, comorbidities, and medication use. Logistic regression and Cox proportional hazards models assessed the associations between HGI and in-hospital, 30-day, and 1-year all-cause mortality, adjusting for age, sex, race, comorbidities, laboratory results, and relevant treatments. Restricted cubic spline (RCS) analysis was performed to examine potential non-linear relationships. We used sensitivity analyses to increase the confidence in our primary outcome.</p><p><strong>Results: </strong>Patients in the lowest HGI group (T1) had significantly higher in-hospital, 30-day, and 1-year mortality than those in the other two groups. Specifically, T1 showed an 18.6% in-hospital mortality rate, compared with 12.3% and 9.7% in T2 and T3, respectively (p < 0.001). Fully adjusted models revealed that each 1-unit increase in HGI was associated with an approximate 12% reduction in in-hospital mortality risk (OR = 0.88; 95%CI: 0.83-0.93), and an 3% decreased risk of 1-year all-cause mortality (HR 0.97; 95%CI0.94~1.00). RCS analysis indicated a J-shaped relationship between HGI and mortality, underscoring the heightened risk associated with very low HGI. We conducted sensitivity analyses by separately excluding missing data, diagnosed sepsis, and diagnosed hepatic impairment, consistent with the primary analysis.</p><p><strong>Conclusions: </strong>In critically ill HF patients, extremely low HGI levels correlate with poorer short- and long-term survival. These findings suggest that HGI could serve as an adjunct risk stratification tool, prompting closer monitoring and potential intervention in patients with markedly low HGI.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"317"},"PeriodicalIF":2.0000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020299/pdf/","citationCount":"0","resultStr":"{\"title\":\"The relationship between hemoglobin glycation index and all-cause mortality in ill critically patients with heart failure: a retrospective study in MIMIC-IV database.\",\"authors\":\"Yulong Wang, Shanshan Tang, Haokun Liu, Yongle Li\",\"doi\":\"10.1186/s12872-025-04711-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Heart failure (HF) is a major cause of mortality in critically ill patients and often requires intensive care. The hemoglobin glycation index (HGI), defined as the difference between predicted glycated hemoglobin (HbA1c) and measured HbA1c, may provide additional prognostic insights beyond traditional glycemic metrics.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 8,098 adult patients with HF from the MIMIC-IV database (2008-2022). All were first-time ICU admissions with available hematologic and metabolic data. Patients were stratified into three groups (T1 ≤ - 1.26, - 1.26 < T2 < 1.74, T3 ≥ 1.74) based on HGI. Baseline characteristics were recorded within 24 h of ICU admission, including demographic data, disease severity scores, comorbidities, and medication use. Logistic regression and Cox proportional hazards models assessed the associations between HGI and in-hospital, 30-day, and 1-year all-cause mortality, adjusting for age, sex, race, comorbidities, laboratory results, and relevant treatments. Restricted cubic spline (RCS) analysis was performed to examine potential non-linear relationships. We used sensitivity analyses to increase the confidence in our primary outcome.</p><p><strong>Results: </strong>Patients in the lowest HGI group (T1) had significantly higher in-hospital, 30-day, and 1-year mortality than those in the other two groups. Specifically, T1 showed an 18.6% in-hospital mortality rate, compared with 12.3% and 9.7% in T2 and T3, respectively (p < 0.001). Fully adjusted models revealed that each 1-unit increase in HGI was associated with an approximate 12% reduction in in-hospital mortality risk (OR = 0.88; 95%CI: 0.83-0.93), and an 3% decreased risk of 1-year all-cause mortality (HR 0.97; 95%CI0.94~1.00). RCS analysis indicated a J-shaped relationship between HGI and mortality, underscoring the heightened risk associated with very low HGI. We conducted sensitivity analyses by separately excluding missing data, diagnosed sepsis, and diagnosed hepatic impairment, consistent with the primary analysis.</p><p><strong>Conclusions: </strong>In critically ill HF patients, extremely low HGI levels correlate with poorer short- and long-term survival. These findings suggest that HGI could serve as an adjunct risk stratification tool, prompting closer monitoring and potential intervention in patients with markedly low HGI.</p>\",\"PeriodicalId\":9195,\"journal\":{\"name\":\"BMC Cardiovascular Disorders\",\"volume\":\"25 1\",\"pages\":\"317\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020299/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cardiovascular Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12872-025-04711-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-025-04711-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:心力衰竭(HF)是危重患者死亡的主要原因,通常需要重症监护。血红蛋白糖化指数(HGI),定义为预测的糖化血红蛋白(HbA1c)和测量的HbA1c之间的差异,可以提供比传统的血糖指标更多的预后见解。方法:我们对来自MIMIC-IV数据库(2008-2022)的8098例成年HF患者进行了回顾性分析。所有患者均为首次入住ICU且有血液学和代谢数据。将患者分为三组(T1≤- 1.26,- 1.26)。结果:最低HGI组(T1)患者的住院死亡率、30天死亡率和1年死亡率均显著高于其他两组。具体来说,T1期住院死亡率为18.6%,T2期和T3期分别为12.3%和9.7% (p结论:在危重HF患者中,极低的HGI水平与较差的短期和长期生存相关。这些发现表明,HGI可以作为一种辅助的风险分层工具,促进对明显低HGI患者进行更密切的监测和潜在的干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The relationship between hemoglobin glycation index and all-cause mortality in ill critically patients with heart failure: a retrospective study in MIMIC-IV database.

Background: Heart failure (HF) is a major cause of mortality in critically ill patients and often requires intensive care. The hemoglobin glycation index (HGI), defined as the difference between predicted glycated hemoglobin (HbA1c) and measured HbA1c, may provide additional prognostic insights beyond traditional glycemic metrics.

Methods: We conducted a retrospective analysis of 8,098 adult patients with HF from the MIMIC-IV database (2008-2022). All were first-time ICU admissions with available hematologic and metabolic data. Patients were stratified into three groups (T1 ≤ - 1.26, - 1.26 < T2 < 1.74, T3 ≥ 1.74) based on HGI. Baseline characteristics were recorded within 24 h of ICU admission, including demographic data, disease severity scores, comorbidities, and medication use. Logistic regression and Cox proportional hazards models assessed the associations between HGI and in-hospital, 30-day, and 1-year all-cause mortality, adjusting for age, sex, race, comorbidities, laboratory results, and relevant treatments. Restricted cubic spline (RCS) analysis was performed to examine potential non-linear relationships. We used sensitivity analyses to increase the confidence in our primary outcome.

Results: Patients in the lowest HGI group (T1) had significantly higher in-hospital, 30-day, and 1-year mortality than those in the other two groups. Specifically, T1 showed an 18.6% in-hospital mortality rate, compared with 12.3% and 9.7% in T2 and T3, respectively (p < 0.001). Fully adjusted models revealed that each 1-unit increase in HGI was associated with an approximate 12% reduction in in-hospital mortality risk (OR = 0.88; 95%CI: 0.83-0.93), and an 3% decreased risk of 1-year all-cause mortality (HR 0.97; 95%CI0.94~1.00). RCS analysis indicated a J-shaped relationship between HGI and mortality, underscoring the heightened risk associated with very low HGI. We conducted sensitivity analyses by separately excluding missing data, diagnosed sepsis, and diagnosed hepatic impairment, consistent with the primary analysis.

Conclusions: In critically ill HF patients, extremely low HGI levels correlate with poorer short- and long-term survival. These findings suggest that HGI could serve as an adjunct risk stratification tool, prompting closer monitoring and potential intervention in patients with markedly low HGI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.50
自引率
0.00%
发文量
480
审稿时长
1 months
期刊介绍: BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信